Similar articles

• Genetic factors in Graves' ophthalmopathy.

  Frecker M, Stenszky V, Balazs C, Kozma L, Kraszits E, Farid NR. Frecker M, et al. Clin Endocrinol (Oxf). 1986 Nov;25(5):479-85. doi: 10.1111/j.1365-2265.1986.tb03599.x. Clin Endocrinol (Oxf). 1986. PMID: 3113776
• The role of HLA antigens in the manifestation and course of Graves' disease.

  Stenszky V, Kozma L, Balazś C, Bear JC, Farid NR. Stenszky V, et al. Mol Biol Med. 1986 Feb;3(1):53-62. Mol Biol Med. 1986. PMID: 3485758
• Heterogeneity by cluster analysis techniques of Graves' patients typed for HLA DR and IgG heavy chain markers.

  Frecker MF, Preus M, Kozma L, Krasrits E, Stenszky V, Balazś C, Farid NR. Frecker MF, et al. Mol Biol Med. 1986 Feb;3(1):63-71. Mol Biol Med. 1986. PMID: 3083192
• [Pathogenesis of diffuse toxic goiter].

  Neĭmark II, Kalinin AP. Neĭmark II, et al. Sov Med. 1991;(8):37-40. Sov Med. 1991. PMID: 1763358 Review. Russian. No abstract available.
• Graves' ophthalmopathy: pathogenesis and clinical implications.

  Major BJ, Busuttil BE, Frauman AG. Major BJ, et al. Aust N Z J Med. 1998 Feb;28(1):39-45. doi: 10.1111/j.1445-5994.1998.tb04457.x. Aust N Z J Med. 1998. PMID: 9544385 Review. No abstract available.